Muse (alprostadil) / Viatris - LARVOL DELTA

Association of Phosphodiesterase-5 Inhibitors Versus Alprostadil With Survival in Men With Coronary Artery Disease. (PubMed, J Am Coll Cardiol) - "In men with stable coronary artery disease, treatment with PDE5i is associated with lower risks of death, MI, heart failure, and revascularization compared with alprostadil treatment. Although the decrease in all-cause mortality was PDE5i dose dependent, the data do not permit the inference of causality or any clinical benefits of PDE5i because of the observational study design."

Journal • Cardiovascular • Congestive Heart Failure • Coronary Artery Disease • Erectile Dysfunction • Heart Failure • Myocardial Infarction • Peripheral Arterial Disease

Effect of alprostadil in the treatment of intensive care unit patients with acute renal injury. (PubMed, World J Clin Cases) - "Alprostadil-assisted CVVH in the treatment of severely ill patients with AKI can effectively improve the renal resistance index and partial pressure of urine oxygen, and has a positive effect on improving renal function."

Clinical • Journal • Acute Kidney Injury • Critical care • Nephrology • Renal Disease

Alprostadil alleviates liver injury in septic rats via TLR4/NF-κB pathway. (PubMed, Eur Rev Med Pharmacol Sci) - "Alp alleviates liver injury in septic rats by inhibiting the TLR4/NF-κB pathway."

IO biomarker • Journal • Hepatology • Liver Failure • TNFA

Frequency and anatomic distribution of arterial obstructions in patients with vasculogenic erectile dysfunction not responding to intracavernous prostaglandin. (PubMed, Vasa) - " Arterial obstructions amenable to endovascular revascularization are frequent in patients non-responsive to intracavernosal prostaglandin administration. Therapeutic strategies in ED patients non-responsive to conservative measures should therefore consider endovascular treatment opportunities."

Clinical • Journal • Erectile Dysfunction

Efficiency of intracavernosal alprostadil and oral clomiphene citrate combination treatment in penile vasculogenic erectile dysfunction patients accompanied by late-onset hypogonadism. (PubMed, Andrologia) - "A significant recovery was observed in IIEF-15 subscores, EHS and SEP2-SEP3 results. In PVED patients accompanied by LOH, intracavernosal alprostadil and oral CC combination is an efficient, low cost, safely applicable and tolerable treatment."

Clinical • Journal • Erectile Dysfunction

Prediction and primary prevention of major vascular complications in systemic sclerosis. (PubMed, Eur J Intern Med) - "in SSc patients, our data confirm the role of arthritis and dyspnea as independent predictors of major vascular complications, in particular in MVCs-naïve patients. Prostanoids, sildenafil and ARBs, even in absence of a primary preventive action, might help in slowing disease progression and postponing the onset of MVCs."

Journal • Fibrosis • Hypertension • Immunology • Pulmonary Arterial Hypertension • Respiratory Diseases • Rheumatology • Scleroderma • Systemic Sclerosis

Effects of alprostadil combined with tanshinone IIa injection on microcirculation disorder, outcomes, and cardiac function in AMI patients after PCI. (PubMed, Ann Palliat Med) - "For AMI patients after PCI, alprostadil combined with tanshinone IIa injection can effectively improve microcirculation and ventricular remodeling, improve cardiac function and reduce the occurrence of MACEs. This combination can be widely used in clinical practice."

Clinical • Journal • Atherosclerosis • Atrial Fibrillation • Cardiovascular • Congestive Heart Failure • Dyslipidemia • Heart Failure • Myocardial Infarction

Generating comprehensive comparative evidence on various interventions for penile rehabilitation in patients with erectile dysfunction after radical prostatectomy: a systematic review and network meta-analysis. (PubMed, Transl Androl Urol) - "Our findings indicated that vacuum constriction devices (VCD) ranked 1st which meant that patients in VCD group had the best effect regarding mean IIEF scores within 3 months after RP, and no significant difference was observed between VCD and VCD with 20 mg/day tadalafil (V20DT) (MD: 5.44; 95% CI: -0.81 to 11.69). VCD and 50 mg/day sildenafil (VC50DS) showed superiority over 50 mg/day sildenafil (50DS) (MD: 3.75; 95% CI: 2.74-4.76) and intraurethral alprostadil 125-250 µg (MD: 3.05; 95% CI: 0.38 to 5.72), respectively...Monotherapy appeared to have similar efficacy in terms of mean IIEF scores and proportion of patients return to baseline, and the effect of phosphodiesterase type 5 inhibitors (PDE5is) did not seem to be affected by the patterns of administration (regular or on demand). The combination therapy showed certain advantages over monotherapy, and we recommended the combination of VCD and PDE5is to be considered in the clinical management of penile..."

Journal • Retrospective data • Review • Erectile Dysfunction

Beyond-use Date of Trimix: A Reproducible Stability Study Using Bracketing Design. (PubMed, Int J Pharm Compd) - "The consistent results confirmed the reproducibility of the bracketing designs used to determine the beyond-use dates of Trimix. The clinical value of these results stems from the availability of accurate and widely applicable stability data that can be referenced to establish beyond use dates of a number of Trimix preparations with various strength combinations."

Journal • Erectile Dysfunction

Alprostadil Continuous Intravenous Infusion in Bridging Cardiac Transplant in Severe Heart Failure Patients (clinicaltrials.gov) - P3; N=500; Not yet recruiting; Sponsor: Biopeutics Co., Ltd; Trial completion date: Dec 2022 ➔ Dec 2024; Trial primary completion date: Jun 2021 ➔ Nov 2021

Clinical • Trial completion date • Trial primary completion date • Cardiovascular • Congestive Heart Failure • Heart Failure • Transplantation

Differences in Penile Hemodynamic Profiles in Patients with Erectile Dysfunction and Anxiety. (PubMed, J Clin Med) - "If further studies confirm the existence of a distinct hemodynamic profile in patients with severe anxiety, sampling the PSV and the EDV values could be proposed, for detecting patients with severe anxiety-related ED. Dynamic PCDU could be considered an accurate diagnostic test in patients with non-organic ED, since zero false-positive results were found in the present study. PSV in the flaccid state is not able to discriminate between arterial- or non-organic ED."

Clinical • Journal • CNS Disorders • Erectile Dysfunction • General Anxiety Disorder • Mood Disorders • Psychiatry

Combination therapy with topical alprostadil and phosphodiesterase-5 inhibitors after failure of oral therapy in patients with erectile dysfunction: a prospective, two-arm, open-label, non-randomized study. (PubMed, Int J Impot Res) - "Topical alprostadil 300 μg/100 mg (Virirec®) was the treatment assigned to Group A, while the combination therapy with the last PDE5I taken (at the maximum recommended dose) plus topical alprostadil 300 μg/100 mg (Virirec®) was assigned to Group B. After 3 months from assignment to groups were evaluated IIEF-5, SEP-2 and SEP-3 regarding the last sexual intercourse, and Global Assessment Questionnaire-Questions 1 and 2 (GAQ-1 and GAQ-2)...Fifty-two patients were previously treated with sildenafil 100 mg (30.6%), 6 with vardenafil 20 mg (3.5%), 56 with tadalafil 20 mg (32.9%), and 56 with avanafil 200 mg (32.9%)...No statistically significant difference was recorded between the AEs of the two groups, except for facial flushing that was reported only in Group B (p = 0.021). The combination therapy with topical alprostadil and PDE5I seems to be more effective than topical alprostadil alone without worsening the safety of the treatment."

Clinical • Combination therapy • Journal • Erectile Dysfunction

Effect of tadalafil 5mg daily treatment on penile haemodynamics in patients with erectile dysfunction (PubMed, Rev Int Androl) - "Tadalafil 5mg daily treatment for 3 months did not result in significant modifications to VPS and AS. There was clinical improvement according to the questionnaires after three months of treatment, which was not maintained at 6 months. Neither a clinical-radiological correlation nor a haemodynamic value predicting response to treatment could be established."

Clinical • Journal • Erectile Dysfunction

The clinical effectiveness and safety of alprostadil combined with alpha lipoic acid in the treatment of diabetic peripheral neuropathy: A protocol for systematic review and meta-analysis. (PubMed, Medicine (Baltimore)) - "This study will draw reliable evidence-based medical evidence for alprostadil combined with Alpha lipoic acid in the treatment of diabetic peripheral neuropathy, thus providing help for the clinical treatment of diabetic peripheral neuropathy."

Journal • Retrospective data • Review • Diabetes • Diabetic Neuropathy • Gastroenterology • Gastrointestinal Disorder • Metabolic Disorders • Pain

Successful Treatment of Refractory Ischemic Diabetic Foot Ulcers by Combination Therapy of Autologous Platelet-rich Gel and Topical β Adrenergic Receptor Blocker: a Case Report (PubMed, Sichuan Da Xue Xue Bao Yi Xue Ban) - "The specific scheme used clopidogrel for antiplatelet agglutination, Low Molecular Weight Heparin (Clexane) and warfarin for anticoagulation, lipo-alprostadil for vasodilation, as well as local debridement and ultrasonic debridement...So the patient was treated with vacuum-assisted closure and autologous platelet-rich gel therapy for the next 7 weeks, then applied with 1 drop of timolol maleate 0.5% ophthalmic solution per cm wound area every other day for another 6 weeks, the wound rapidly healed and re-epithelialized basically. The follow-up for 5 weeks showed that the wound healed completely without any discomfort. No side effect was found."

Clinical • Combination therapy • Journal • Cardiovascular • Chronic Kidney Disease • Diabetes • Hematological Disorders • Hypertension • Metabolic Disorders • Nephrology • Ophthalmology • Renal Disease • Respiratory Diseases • Thrombosis

Is topical alprostadil an usable and reliable alternative to intracavernous injection for penile dynamic duplex ultrasonography? (PubMed, Andrologia) - "Patients reported less pain/discomfort during the procedure in case of topical alprostadil use and an overall preference towards this examination modality. Topical alprostadil could represent a usable and reliable alternative to intracavernous injection for PDDU, with less discomfort and greater preference by patients."

Journal • Erectile Dysfunction • Pain

Is Kelami's Method Still Useful in the Smartphone Era? The Virtual 3-Dimensional Reconstruction of Penile Curvature in Patients With Peyronie's Disease: A Pilot Study. (PubMed, J Sex Med) - "Our pilot study has shown that it is possible to quickly obtain a sequence of photographs to create an accurate virtual 3D model of the penis of patients with Peyronie's disease, helping the patients and the surgeon during preoperative counseling and surgical planning. Pavone C, Abrate A, Altomare S, et al. Is Kelami's Method Still Useful in the Smartphone Era? The Virtual 3-Dimensional Reconstruction of Penile Curvature in Patients With Peyronie's Disease: A Pilot Study. J Sex Med 2020;XX:XXX-XXX."

Clinical • Journal • Fibrosis

Physical compatibility of alprostadil with selected drugs commonly used in the neonatal intensive care units. (PubMed, Eur J Pediatr) - "No modifications of one pH unit or more was detected in any drug pair over time. Alprostadil was considered physical compatible with 13 drugs (adrenalin, amiodarone, calcium gluconate, dobutamine, dopamine, fentanyl, flecainide, furosemide, heparin, ketamine, midazolam, milrinone and morphine). What is New: • Alprostadil was compatible with 13 drugs commonly used in neonatal intensive care units. • Insulin was considered incompatible with alprostadil, and incompatibility cannot be ruled out for cisatracurium, dexmedetomidine and noradrenalin with alprostadil."

Journal • Critical care

Alprostadil Injection Attenuates Coronary Microembolization-Induced Myocardial Injury Through GSK-3β/Nrf2/HO-1 Signaling-Mediated Apoptosis Inhibition. (PubMed, Drug Des Devel Ther) - "Additionally, it was unveiled that the protective effects of alprostadil injection inhibit CME-induced myocardial apoptosis in the myocardium potentially through regulation of the GSK-3β/Nrf2/HO-1 signaling pathway. Alprostadil injection seems to significantly suppress oxidative stress, alleviate myocardial apoptosis in the myocardium, and improve cardiac systolic and diastolic functions following CME by regulating the GSK-3β/Nrf2/HO-1 signaling pathway."

Journal • Cardiovascular

PGE1-assisted treatment of microcirculation disturbance in complicated falciparum malaria (PubMed, Anaesthesist) - "Furthermore, the clearance course of the plasmodia was delayed under artemisinin-based combination therapy. Prolonged hemolysis required multiple transfusions."

Journal • CNS Disorders • Critical care • Depression • Hematological Disorders • Infectious Disease • Malaria • Septic Shock • Thrombosis

How can we preserve sexual function after ablative surgery for benign prostatic hyperplasia? (PubMed, Curr Drug Targets) - "Regarding ejaculation disorders (retrograde ejaculation or anejaculation): medical therapy with a-agonists (pseudoephedrine), sperm retrieval from the urine, bladder neck reconstruction, prostatic massage, electroejaculation, penile vibratory stimulation and surgical sperm retrieval are the available treatment options. Further, high quality studies are required to investigate potential side effects of BPE surgery on sexual function and efficient treatment methods to manage them."

Journal • Benign Prostatic Hyperplasia • Erectile Dysfunction • Sexual Disorders • Thermal Injury

Effects of alprostadil in β-aminopropanitrile induced aortic dissection in a murine model (PubMed, Zhonghua Xin Xue Guan Bing Za Zhi) - " EP4 expression is upregulated in BAPN induced aortic dissection mouse model. No protective effects are observed post alprostadil treatment in this model probably due to the reduced expression of EP4."

Journal • Preclinical • Musculoskeletal Diseases • Orthopedics

Provocative angiography for lower gastrointestinal bleeding. (PubMed, Jpn J Radiol) - "Provocative angiography enabled the site of lower gastrointestinal bleeding to be identified in 6 of 12 cases (50.0%) when it could not be identified by conventional angiography, and in all 6 cases hemostasis was effectively achieved by embolization."

Journal • Gastroenterology • Gastrointestinal Disorder • Hematological Disorders

Pharmacological treatment for Buerger's disease. (PubMed, Cochrane Database Syst Rev) - "Moderate-certainty evidence suggests that intravenous iloprost (prostacyclin analogue) is more effective than aspirin for eradicating rest pain and healing ischaemic ulcers in Buerger's disease, but oral iloprost is not more effective than placebo. Very low and low-certainty evidence suggests there is no clear difference between prostacyclin (iloprost and clinprost) and the prostaglandin analogue alprostadil for healing ulcers and relieving pain respectively in severe Buerger's disease. Very low-certainty evidence suggests there is no clear difference in pain scores and amputation rates between folic acid and placebo, in people with Buerger's disease and hyperhomocysteinaemia. Further well designed RCTs assessing the effectiveness of pharmacological agents (intravenous or oral) in people with Buerger's disease are needed."

Journal • Review • Atherosclerosis • Dyslipidemia • Pain

Promising role of medicinal plants in the regulation and management of male erectile dysfunction. (PubMed, Biomed Pharmacother) - "It also provides medicinal plants that are proven effective in vivo and in vitro for the mitigation and treatment of male ED. This knowledge could be used in the future in drug discovery for the development of more natural drugs with no side effects."

Journal • Review • Erectile Dysfunction